Table 1. Patient characteristics Patient... | American Society of Hematology

Table 1.

Patient characteristics

Patient no.	Age, y	Sex	Stage	Response	CD30⁺	ALK-1⁺	CD25⁺	sCD30 level, U/mL	sIL-2R level, pg/mL
1	34	M	IVA	CR	Positive	Negative	Negative	217	517
2	19	M	IIIA	CR	Positive	ND	ND	534	13 918
3	38	M	IVB	CR	Positive	Positive^*	ND	34 065	470 575
4	21	M	IIA	CR†	Positive	Positive	Positive	1 155	8 313†
5	21	M	IIB	CR	Positive	Positive^*	ND	508	6 328
6	29	F	IIIA	CR	Positive	Positive	Positive	3 971	39 297
7	34	M	IV	CR	Positive	Positive	ND	21 480	191 483
8	24	F	IV	PD	Positive	Positive	Positive	ND	18 900§
9	68	F	II	CR	Positive	Positive	ND	ND	ND
10	60	M	IV	CR	Positive	Negative	Negative	488	2 183

Patient no.	Age, y	Sex	Stage	Response	CD30⁺	ALK-1⁺	CD25⁺	sCD30 level, U/mL	sIL-2R level, pg/mL
1	34	M	IVA	CR	Positive	Negative	Negative	217	517
2	19	M	IIIA	CR	Positive	ND	ND	534	13 918
3	38	M	IVB	CR	Positive	Positive^*	ND	34 065	470 575
4	21	M	IIA	CR†	Positive	Positive	Positive	1 155	8 313†
5	21	M	IIB	CR	Positive	Positive^*	ND	508	6 328
6	29	F	IIIA	CR	Positive	Positive	Positive	3 971	39 297
7	34	M	IV	CR	Positive	Positive	ND	21 480	191 483
8	24	F	IV	PD	Positive	Positive	Positive	ND	18 900§
9	68	F	II	CR	Positive	Positive	ND	ND	ND
10	60	M	IV	CR	Positive	Negative	Negative	488	2 183

Normal value for sCD30 is less than 18 U/mL and that for sIL-2R less than 3600 pg/mL.

CR indicates complete response; ND, not done; PD, progressive disease.

Cytoplasmic ALK-1 staining, otherwise both cytoplasmic and nuclear staining.

Patient 4 experienced a relapse, at which point his sIL-2R level was measured at 95 661 pg/mL.

Sample was obtained at the start of the second cycle.